Serous Carcinoma

Definition

Serous carcinoma is a type of epithelial carcinoma most commonly arising in the ovary, fallopian tube, or peritoneum. It is classified as either high-grade or low-grade, with high-grade serous carcinoma (HGSC) being the most aggressive and common form.

Epidemiology

• Most common type of ovarian cancer (high-grade serous: ~70–80% of cases).
• Often diagnosed at advanced stage due to nonspecific symptoms.

Pathogenesis

• High-grade serous carcinoma (HGSC): usually associated with TP53 mutations and often arises from the fallopian tube fimbriae.
• Low-grade serous carcinoma (LGSC): associated with KRAS, BRAF, or ERBB2 mutations.
• Can involve BRCA1/2 mutations (germline or somatic) — important for therapy decisions (PARP inhibitors).

Histology

• Papillary or solid architecture.
• High-grade: marked nuclear atypia, frequent mitoses.
• Low-grade: mild atypia, less mitotic activity.

Clinical Features

• Abdominal bloating, pain, early satiety.
• Often advanced stage at presentation.
• May present with ascites or pleural effusion in metastatic disease.

Diagnostics

• Imaging: CT scan or MRI of the pelvis/abdomen.
• Tumor markers: CA-125 elevated in many cases.
• Histopathology: confirms serous histology.
• Molecular testing: TP53, BRCA1/2, HRD status (therapeutic implications).

Treatment (Oncology Pharmacy Focus)

Surgery

• Cytoreductive surgery (goal: no gross residual disease).

Chemotherapy

• First-line: Platinum + taxane regimen (Carboplatin + Paclitaxel).
• Dose-dense or intraperitoneal therapy may be used in selected patients.

Targeted Therapy

• PARP inhibitors (Olaparib, Niraparib, Rucaparib): in BRCA-mutated or HRD-positive patients.
• Anti-angiogenic agents (Bevacizumab) in combination with chemotherapy or maintenance.

Considerations for Pharmacy

• Monitor for myelosuppression, neuropathy, nephrotoxicity, and GI toxicity.
• Drug interactions: PARP inhibitors (CYP3A substrates), Bevacizumab (hypertension, bleeding risk).
• Supportive care: antiemetics, growth factors, thromboprophylaxis in high-risk patients.

Prognosis

• High-grade serous: aggressive, often advanced stage, median survival ~40–50 months with optimal therapy.
• Low-grade serous: slower progression, relatively chemoresistant.